Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
2013 ◽
Vol 71
(Suppl 3)
◽
pp. 60.3-61
2013 ◽
Vol 24
(3)
◽
pp. 410-418
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 717.1-717